Genmab A/S

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 13/09/2024 BST			5-day change	1st Jan Change
1,800.00 ^DKK	+1.18%		-3.23%	-16.47%

09-09	Truist Lowers Price Target on Genmab to $50 From $53, Maintains Buy Rating	MT
09-04	Transcript : Genmab A/S Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 01:05 PM

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Genmab A/S

Truist Lowers Price Target on Genmab to $50 From $53, Maintains Buy Rating	09-09	MT
Transcript : Genmab A/S Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 01:05 PM	09-04
Morgan Stanley Upgrades Genmab to Equalweight, Price Target is $31	09-04	MT
HOOKIPA Pharma Names Julie O'Neill Nonexecutive Chair	08-30	MT
European Equities Close Lower in Tuesday Trading; Euro Area, EU Inflation Rises Slightly	08-20	MT
Global markets live: Rio Tinto, GSK, Palo Alto, GM, Lowe's...	08-20
Genmab Wins Conditional EU Approval for Follicular Lymphoma Antibody	08-20	MT
AbbVie, Genmab Lymphoma Treatment Gets European Commission Marketing Authorization	08-19	DJ
Genmab, AbbVie Get Conditional European Commission Approval for Lymphoma Treatment	08-19	MT
Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	08-19	CI
Genmab Names First Chief Technology, Chief Commercial Officers; COO to Exit	08-16	MT
Genmab COO Anthony Mancini Departs; Firm Names New CTO, CCO	08-16	MT
Genmab Operations Chief Anthony Mancini Departing	08-16	MT
Genmab A/S Announces Executive Changes	08-16	CI
AbbVie Inc. Announces Ontario and Quebec Are First Provinces to Reimburse Subcutaneous Epkinly? (Epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access Process	08-15	CI
GENMAB : Better-than-expected Q2 + guidance upgrade	08-09
Genmab: updates 2024 financial forecasts	08-09	CF
Genmab's Interim Q2 Earnings, Revenue Climb; Increases 2024 Revenue Guidance	08-09	MT
Genmab Posts Higher H1 Profit; Revenue Advances	08-09	MT
Transcript : Genmab A/S, H1 2024 Earnings Call, Aug 08, 2024	08-08
Genmab A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08-08	CI
Global markets live: Amazon, Intel, Boeing, Robinhood, KKR, Zillow...	08-08
Genmab A/S Revises Earnings Guidance for the Year 2024	08-08	CI
Tranche Update on Genmab A/S's Equity Buyback Plan announced on March 25, 2024.	08-08	CI
Genmab to Go Solo in Cancer Drug Development as BioNTech Exits	08-05	MT

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.2%); - income from research and development (12.4%); - other (4.4%): primarily income from partnership agreement. At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Denmark accounts for all net sales.

Employees

2,526

Sector

Biotechnology & Medical Research

Calendar

06/11/2024 - Q3 2024 Earnings Release

More about the company